BioAge Labs' Lead Drug BGE-102 Enters Phase 2 for Cardiovascular Risk; Topline Data Expected H2 2026
BIOA has more than doubled off its 52-week low of $4.065.
Summary
BioAge Labs has dosed the first participant in its Phase 2 QUELL-CV trial for BGE-102, an NLRP3 inhibitor targeting cardiovascular risk. This follows highly positive Phase 1 data for BGE-102 reported in March and May, which demonstrated significant reductions in inflammatory biomarkers. Advancing the lead candidate into Phase 2 is a critical de-risking step for the company, moving it closer to potential commercialization in a large market. Topline data from the QUELL-CV trial is anticipated in the second half of 2026.
At the time of this announcement, BIOA was trading at $19.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $881.9M. The 52-week trading range was $4.07 to $24.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.